Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, Aug. 28, 2026 SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today...
PR Newswire
More News
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in...
PR Newswire
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
Zacks
Retail Sales Weaken in July
Retail Sales Weaken in July
Zacks
U.S. Stock Futures Mixed, Heads for a Winning Week
U.S. Stock Futures Mixed, Heads for a Winning Week.
Zacks
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call
Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial dataread more...
Benzinga
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of +40.29% and -6.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
Nektar Therapeutics Announces Second Quarter 2026 Financial Results Nektar Therapeutics Announces Second Quarter 2026 Financial Results PR Newswire SAN FRANCISCO, Aug. 13, 2026 SAN FRANCISCO, Aug. 13, 2026 /PRNewswire/ -- Nektar Therapeutics(Nasdaq: NKTR), a clinical-stage biotechnology company...
PR Newswire
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm PR Newswire NEW YORK, Aug. 11, 2026 NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating...
PR Newswire

Advertisement|Remove ads.